The pharmacokinetics of irbesartan in renal failure and maintenance hemodialysis

Clinical Pharmacology and Therapeutics
D A SicaN F Ford

Abstract

An open-label, multiple-dose, parallel-group study was conducted to evaluate the pharmacokinetics of the angiotensin II receptor antagonist irbesartan in subjects with varying degrees of renal function. Forty subjects were divided into four treatment groups on the basis of 24-hour creatinine clearance (CLCR): normal renal function (> 75 ml/min/1.73 m2), mild to moderate renal impairment (30 to 74 ml/min/1.73 m2), severe renal impairment (< 30 ml/min/1.73 m2), and maintenance hemodialysis. Subjects received 100 mg irbesartan daily for 8 days (or 300 mg daily for 9 days for the hemodialysis group). Serial blood and urine samples were collected for 24 hours after the first and last of eight successive daily doses. In addition, arterial and venous blood samples were collected during two hemodialysis sessions from subjects requiring maintenance hemodialysis. There was no statistically significant linear relationship between CLCR and maximum plasma concentrations, dose-adjusted area under the plasma concentration time curve values on days 1 or 8, or any other pharmacokinetic parameters among the renal function groups studied. There was no indication of drug accumulation with repetitive dosing. In the subjects receiving hemodialysis, ...Continue Reading

References

Aug 1, 1992·Kidney International·H R Brunner
Apr 1, 1991·American Journal of Hypertension·Y ChristenH R Brunner
Jul 1, 1991·British Journal of Clinical Pharmacology·J H AhmedH L Elliott
Jul 1, 1986·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·T P Gibson
Jan 1, 1987·European Journal of Clinical Pharmacology·D A SicaF Eshelman
Nov 1, 1980·Kidney International·M W Anders
Jan 1, 1995·Hypertension·A H van den MeirackerA J Man In 't Veld
Jul 1, 1994·American Journal of Hypertension·A Zanchetti
Jan 1, 1997·Clinical Pharmacokinetics·Y W LamR L Talbert

❮ Previous
Next ❯

Citations

Jun 21, 2001·The Journal of Clinical Hypertension·D A Sica
May 16, 2009·Nihon yakurigaku zasshi. Folia pharmacologica Japonica·Yusuke Ariyoshi, Keigo Mizumoto
Apr 23, 1999·Pharmacotherapy·D A Sica, N K Hollenberg
Sep 29, 2011·Integrated Blood Pressure Control·Valentina ForniMichel Burnier
Oct 15, 2013·Vascular Health and Risk Management·Fotini Gialama, Nikos Maniadakis
Jul 5, 2005·Expert Opinion on Investigational Drugs·C I Johnston
Aug 26, 2010·Journal of Pharmacological Sciences·Makiko NakamuraKimiyoshi Ichida
Sep 5, 2001·Advances in Renal Replacement Therapy·B Chavers, H W Schnaper
Jul 17, 2001·Journal of Clinical Pharmacology·A SakarcanM R Marino
Feb 14, 2003·Journal of the Renin-angiotensin-aldosterone System : JRAAS·Domenic A Sica, Todd W B Gehr
Mar 20, 2004·Expert Review of Cardiovascular Therapy·Bernard Waeber, Michel Burnier
Feb 1, 2002·The Journal of Clinical Hypertension·Domenic A Sica, George L Bakris
Jul 31, 2002·The Journal of Clinical Hypertension·Domenic A Sica, Michael Weber
Jul 8, 2003·Current Hypertension Reports·Domenic A Sica
Jun 1, 2000·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·D A SicaA Fernandez
Jul 8, 2000·Clinical Pharmacokinetics·D A SicaW F Keane
Nov 24, 2004·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Boris SchmidtBernhard Schieffer
Sep 14, 2006·Pharmacological Reviews·Sharon J Gardiner, Evan J Begg
Jun 20, 2002·Journal of Cardiovascular Pharmacology·Maria R Marino, Nimish N Vachharajani
Mar 30, 2016·Current Opinion in Nephrology and Hypertension·Alvin TieuMatthew A Weir
Dec 23, 1998·British Journal of Clinical Pharmacology·N N VachharajaniD S Greene
Jun 8, 2012·High Blood Pressure & Cardiovascular Prevention : the Official Journal of the Italian Society of Hypertension·Claudio Borghi, Arrigo F G Cicero
Jul 17, 2008·Drugs·Katherine F Croom, Greg L Plosker

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.